Patents by Inventor Surender Khurana
Surender Khurana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11905313Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.Type: GrantFiled: November 27, 2018Date of Patent: February 20, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services.Inventor: Surender Khurana
-
Patent number: 11833199Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.Type: GrantFiled: November 16, 2021Date of Patent: December 5, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Surender Khurana
-
Patent number: 11478542Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: GrantFiled: July 16, 2020Date of Patent: October 25, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Patent number: 11353454Abstract: Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.Type: GrantFiled: March 26, 2020Date of Patent: June 7, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Surender Khurana
-
Publication number: 20220072119Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.Type: ApplicationFiled: November 16, 2021Publication date: March 10, 2022Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventor: Surender Khurana
-
Patent number: 11202824Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.Type: GrantFiled: October 31, 2017Date of Patent: December 21, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Surender Khurana
-
Publication number: 20210208160Abstract: Methods of identifying a subject with a Filovirus infection are provided herein. In some embodiments, the method comprises contacting a biological sample containing antibodies from the subject with one or more peptides comprising amino acid sequences of selected Filovirus epitopes, detecting the presence or absence of an immune complex of antibodies from the biological sample with the one or more peptides; and wherein the presence of the immune complex identifies the subject as having Filovirus infection and the absence of the immune complex identifies the subject as not having Filovirus infection. Further provided are isolated peptides for use in such methods, as well as a solid support linked to one or more of the disclosed peptides.Type: ApplicationFiled: January 8, 2021Publication date: July 8, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventor: Surender Khurana
-
Publication number: 20200348299Abstract: Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.Type: ApplicationFiled: March 26, 2020Publication date: November 5, 2020Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventor: Surender Khurana
-
Publication number: 20200345829Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: ApplicationFiled: July 16, 2020Publication date: November 5, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Surender Khurana, Hana Golding
-
Publication number: 20200299335Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.Type: ApplicationFiled: November 27, 2018Publication date: September 24, 2020Applicants: and Human ServicesInventor: Surender Khurana
-
Patent number: 10744193Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: GrantFiled: February 18, 2016Date of Patent: August 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Publication number: 20200054734Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.Type: ApplicationFiled: October 31, 2017Publication date: February 20, 2020Applicant: The United States of America, as represented by the Secretary, Department Health and Human ServiceInventor: Surender Khurana
-
Patent number: 10377798Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.Type: GrantFiled: December 2, 2014Date of Patent: August 13, 2019Assignee: The United States of America, as rerpresented by the Secretary, Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Publication number: 20180110850Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: ApplicationFiled: February 18, 2016Publication date: April 26, 2018Applicant: The United States of America, as Represented by the Secretary, Dept. of Health and Human ServiceInventors: Surender Khurana, Hana Golding
-
Patent number: 9896484Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: GrantFiled: October 19, 2015Date of Patent: February 20, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Publication number: 20160368949Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: ApplicationFiled: October 19, 2015Publication date: December 22, 2016Inventors: Hana Golding, Surender Khurana
-
Publication number: 20160304565Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered) for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.Type: ApplicationFiled: December 2, 2014Publication date: October 20, 2016Inventors: Surender KHURANA, Hana GOLDING
-
Patent number: 9163068Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: GrantFiled: November 2, 2010Date of Patent: October 20, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology TransferInventors: Surender Khurana, Hana Golding
-
Patent number: 9121855Abstract: This invention concerns methods for detecting the presence of an anti-HIV-1 antibody in a biological sample, the method comprising conducting an immunoassay comprising: (a) contacting the biological sample with at least one epitope that is recognized by the anti-HIV-1 antibody, wherein the contacting being under conditions sufficient to permit the anti-HIV-1 antibody if present in the sample to bind to the epitope and form an epitope-anti-HIV-1 antibody complex; (b) contacting the formed epitope-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, the contacting being under conditions sufficient to permit the anti- HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed epitope-anti-HIV-1 antibody complex and form an extended complex; and (c) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentration of the formed extended complex; the epitope being present on a peptide comprising SEQ ID NType: GrantFiled: December 23, 2010Date of Patent: September 1, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hana Golding, Surender Khurana
-
Patent number: 8980546Abstract: This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: GrantFiled: May 21, 2010Date of Patent: March 17, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hana Golding, Surender Khurana